新闻动态
News Information
-
- Clinical guidelines strongly recommend the use of carboxypeptidase in high-dose methotrexate antidot
Acute kidney injury caused by high dose methotrexate is a severe and fatal toxicity. Carboxypeptidase is an fda-approved drug used to treat kidney dysfunction caused by high doses of methotrexate.
-
- FDA approves the first recombinant enzyme for the treatment of mucopolysaccharide VII syndrome
Ultragenyx Pharmaceutical approved Mepsevii (vestronidase alfa-vjbk) to treat mucosaccharide storage syndrome (MPS VII), also known as Sly syndrome, in children and adults.
-
- FDA approved amparsabiv for the treatment of secondary hyperparathyroidism
The us food and drug administration has approved its drug to treat secondary hyperparathyroidism in patients with chronic kidney disease, amgen said on February 7, 2017.
